GERN Geron Corp

Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference in New York at 1:40 p.m. Eastern Time on Tuesday, September 26, 2017.

A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://wsw.com/webcast/cantor6/gern/. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.

About Geron

Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

CONTACT:

Anna Krassowska, Ph.D.Investor and Media Relations650-473-7765investor@geron.commedia@geron.com